| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | — | — | — | — | — | — | — | — | — | — |
| NIFTY Healthcare TRI | +12.35% | +6.16% | +10.59% | +20.00% | +18.07% | +20.97% | +15.83% | — | — | — |
| Category middle | +8.17% | -0.17% | +5.81% | +1.26% | +0.50% | +10.76% | +8.57% | +12.10% | +12.82% | — |
| Volatility | — |
| Sharpe | — |
| Sortino | — |
| Beta | — |
| Alpha | — |
| Deepest fall | — |
| 1-year periods with a loss | — |
| 5Y SIP XIRR | — |
| Sun Pharmaceutical Industries Limited | 16.32% |
| Divi's Laboratories Limited | 10.78% |
| Laurus Labs Limited | 8.12% |
| Apollo Hospitals Enterprise Limited | 7.54% |
| Dr. Reddy's Laboratories Limited | 7.15% |
| Cipla Limited | 6.73% |
| Torrent Pharmaceuticals Limited | 5.89% |
| Max Healthcare Institute Limited | 5.55% |
| Lupin Limited | 4.23% |
| Aurobindo Pharma Limited | 4.03% |
| Fortis Healthcare Limited | 3.47% |
| Glenmark Pharmaceuticals Limited | 3.00% |
| Pharmaceuticals & Biotechnology | 81.8% |
| Healthcare Services | 18.2% |
Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.